Correction to: Bumetanide Oral Liquid Formulation for the Treatment of Children and Adolescents with Autism Spectrum Disorder: Design of Two Phase III Studies (SIGN Trials)

Detalles Bibliográficos
Autores principales: Crutel, Véronique, Lambert, Estelle, Penelaud, Pierre-François, Albarrán Severo, Cristina, Fuentes, Joaquin, Rosier, Antoine, Hervás, Amaia, Marret, Stéphane, Oliveira, Guiomar, Parellada, Mara, Kyaga, Simon, Gouttefangeas, Sylvie, Bertrand, Marianne, Ravel, Denis, Falissard, Bruno
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2021
Materias:
Correction
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8496673/
https://www.ncbi.nlm.nih.gov/pubmed/33423216
http://dx.doi.org/10.1007/s10803-020-04822-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8496673/
https://www.ncbi.nlm.nih.gov/pubmed/33423216
http://dx.doi.org/10.1007/s10803-020-04822-8

Ejemplares similares